De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer
Alex K. Bryant, K. Nathan Sankar, Lili Zhao, Garth W. Strohbehn, David J. Elliott, Drew Moghanaki, Michael J. Kelley, Nithya Ramnath, Michael D. Green
Topics & Concepts
DurvalumabMedicineStage (stratigraphy)AdjuvantDuration (music)Lung cancerOncologyInternal medicineCancerBiologyImmunotherapyArtLiteraturePaleontologyNivolumabCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations